

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 04/06

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:12:48 ON 10 MAY 2001

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

0.30

FILE 'REGISTRY' ENTERED AT 10:13:59 ON 10 MAY 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9

DICTIONARY FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> s misoprostol/cn

L1 1 MISOPROSTOL/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 59122-46-2 REGISTRY

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11.alpha.,13E)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Cytotec

CN Misoprostil

CN **Misoprostol**

CN SC 29333

FS STEREOSEARCH

DR 62015-39-8, 143913-16-0, 92999-98-9

MF C22 H38 O5

CI COM


LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IMSDIRECTORY, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXLINE, TOXLIT, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Double bond geometry as shown.



711 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

711 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s cyclodextrin/cn

L2 1 CYCLODEXTRIN/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 12619-70-4 REGISTRY

CN **Cyclodextrin** (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Celdex
 CN Celdex CH 20
 CN Celdex CH 30
 CN Celdex SH 20
 CN Celdex SH 40
 CN Cycloamylose
 CN Rhodocap L 20
 CN Ringdex P
 DR 100091-36-9
 MF Unspecified
 CI COM, MAN
 LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
 CAPLUS, CASREACT, CBNB, CEN, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU,
 EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, PIRA, PROMT, TOXLINE,
 TOXLIT, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

3009 REFERENCES IN FILE CA (1967 TO DATE)

966 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3015 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s alprostadil/cn

L3 1 ALPROSTADIL/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 745-65-3 REGISTRY

CN Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-
 (9CI)

(CA INDEX NAME)

OTHER CA INDEX NAMES:

---CN--- Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-,
 (-)-

(8CI)

CN Cyclopentaneheptanoic acid,
 3.alpha.-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-
 (7CI)

OTHER NAMES:

CN (-)-Prostaglandin E1

CN 11.alpha.,15(S)-Dihydroxy-9-oxo-13-trans-prostenoic acid

CN 11.alpha.,15.alpha.-Dihydroxy-9-oxo-13-trans-prostenoic acid

CN **Alprostadil**

CN Alprox TD

CN Caverject

CN 1-PGE1

CN 1-Prostaglandin E1

CN PGE1

CN Prostaglandin E1

CN Prostandin

CN Prostandin 500

CN U 10136

FS STEREOSEARCH

DR 50-83-9, 22299-37-2, 50865-30-0


MF C20 H34 O5

CI COM

LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
 CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL,
 DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB,

IMSDIRECTORY, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR,
 PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.
 Double bond geometry as shown.



8176 REFERENCES IN FILE CA (1967 TO DATE)
 136 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 8179 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> index bioscience
 FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
16.83	17.13

FULL ESTIMATED COST

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS,
 BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT,
 CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE,
 DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 10:15:44 ON 10
 MAY 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
 search error messages that display as 0* with SET DETAIL OFF.

=> s (11 or misoprostol or cytotec or Misoprostil) and (13 or alprostadil or
 Prostaglandin E1 or PGE1 or Prostandin)
 'E1' NOT FOUND
 The E# entered is not currently defined.

=> s (11 or misoprostol or cytotec or Misoprostil) and (13 or alprostadil or
 Prostaglandin E or PGE1 or Prostandin)

66* FILE ADISALERTS
 6 FILE ADISINSIGHT
 1 FILE AGRICOLA
 0* FILE AQUASCI
 2 FILE BIOBUSINESS
 0* FILE BIOCOMMERCE
 384 FILE BIOSIS
 40 FILE BIOTECHNO
 3* FILE CABA
 35 FILE CANCERLIT
 13 FILES SEARCHED...

223* FILE CAPLUS
 0* FILE CEABA-VTB
 3* FILE CONFSCI
 0* FILE CROPB
 0* FILE CROPU
 0* FILE DDFB
 187* FILE DDFU
 0* FILE DGENE
 23 FILES SEARCHED...
 0* FILE DRUGB
 231* FILE DRUGU
 2 FILE DRUGUPDATES
 0* FILE EMBAL
 223 FILE EMBASE
 77* FILE ESBIODBASE
 32 FILES SEARCHED...
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 7* FILE IFIPAT
 5 FILE JICST-EPLUS
 40 FILES SEARCHED...
 0* FILE KOSMET
 30* FILE LIFESCI
 0* FILE MEDICONF
 510 FILE MEDLINE
 1* FILE NTIS
 0* FILE OCEAN
 47 FILES SEARCHED...
 140* FILE PASCAL
 5 FILE PHAR
 0* FILE PHIC
 11* FILE PHIN
 9 FILE PROMT
 291* FILE SCISEARCH
 1 FILE SYNTHLINE
 241 FILE TOXLINE
 55 FILES SEARCHED...
 149 FILE TOXLIT
 94* FILE USPATFULL
 11 FILE WPIDS
 11 FILE WPINDEX

31 FILES HAVE ONE OR MORE ANSWERS, 59 FILES SEARCHED IN STNINDEX

L4 QUE (L1 OR MISOPROSTOL OR CYTOTEC OR MISOPROSTIL) AND (L3 OR
 ALPROSTADIL
 OR PROSTAGLANDIN E OR PGE1 OR PROSTANDIN)

=> d rank

F1	510	MEDLINE
F2	384	BIOSIS
F3	291*	SCISEARCH
F4	241	TOXLINE
F5	231*	DRUGU
F6	223	EMBASE
F7	223*	CAPLUS
F8	187*	DDFU
F9	149	TOXLIT

F10	140*	PASCAL
F11	94*	USPATFULL
F12	77*	ESBIOBASE
F13	66*	ADISALERTS
F14	40	BIOTECHNO
F15	35	CANCERLIT
F16	30*	LIFE SCI
F17	11	WPIDS
F18	11	WPINDEX
F19	11*	PHIN
F20	9	PROMT
F21	7*	IFIPAT
F22	6	ADISINSIGHT
F23	5	JICST-EPLUS
F24	5	PHAR
F25	3*	CABA
F26	3*	CONFSCI
F27	2	BIOBUSINESS
F28	2	DRUGUPDATES
F29	1	AGRICOLA
F30	1	SYNTHLINE
F31	1*	NTIS

=> file f1-f19

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.60

20.73

FILE 'MEDLINE' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'BIOSIS' ENTERED AT 10:20:32 ON 10 MAY 2001

COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'SCISEARCH' ENTERED AT 10:20:32 ON 10 MAY 2001

COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'TOXLINE' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'DRUGU' ENTERED AT 10:20:32 ON 10 MAY 2001

COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 10:20:32 ON 10 MAY 2001

COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 10:20:32 ON 10 MAY 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'TOXLIT' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'PASCAL' ENTERED AT 10:20:32 ON 10 MAY 2001

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2001 INIST-CNRS. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:20:32 ON 10 MAY 2001

CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ESBIOBASE' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ADISALERTS' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Adis International Ltd. (ADIS)

FILE 'BIOTECHNO' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'LIFESCI' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'PHIN' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 PJB Publications Ltd. (PJB)

=> s l4
'CN' IS NOT A VALID FIELD CODE
5 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
13 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
L5 2966 L4

=> s female sexual? dysfunction
13 FILES SEARCHED...
L6 705 FEMALE SEXUAL? DYSFUNCTION

=> s l5 and l6
L7 3 L5 AND L6

=> d ti

L7 ANSWER 1 OF 3 USPATFULL
TI Compositions

=> d 2-3 ti

L7 ANSWER 2 OF 3 USPATFULL
TI Compositions

L7 ANSWER 3 OF 3 USPATFULL
TI Compositions

=> d ibib abs kwic tot

L7 ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 1999:110350 USPATFULL
TITLE: Compositions

INVENTOR(S): Dias Nahoum, Cesar Roberto, P.O. Box 1539, King of
Prussia, PA, United States 19406-0939

	NUMBER	DATE
PATENT INFORMATION:	US 5952361	19990914
APPLICATION INFO.:	US 1998-37097	19980309 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-444130, filed on 18 May 1995, now patented, Pat. No. US 5773457 which is a continuation of Ser. No. US 1995-381945, filed on 15 Feb 1995	

	NUMBER	DATE
PRIORITY INFORMATION:	BR 1992-3277	19920821
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Reamer, James H.	
LEGAL REPRESENTATIVE:	Dinner, Dara L.; Venetianer, Stephen; Kinzig, Charles M.	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1524	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction.**

- - - - -SUMM - In 1986, Ishii et al injected for the first time **prostaglandin E.sub.1** into human corpora cavernosa for the treatment of organic impotence, Ishii, N. et al. "Therapeutic trial with **prostaglandin E.sub.1** for organic impotence". Jap. J. Imp., 1: 54-962 (1986). See also Ishii, N. et al "Intracavernous injection of **prostaglandin E.sub.1** for the treatment of erectile impotence". J. Urol., 141(2): 323-325 (1989). Since it is a drug of natural occurrence in. . .

SUMM . . . following the use of such a combination, von-Heyden et al. J. Urol., 149(5 Pt 2): 1288-1290 (1993). The use of **prostaglandin E.sub.1** is often rejected by patients because of the painfulness of its injection. Waldhauser, M. et al., J. Urol., 140(3): 525-527. .

SUMM . . . Impotence Res., 4(Suppl. 2): A91 (1992)) compared the erectogenic efficiency of 1 mg of SIN-1 (Linsindomin-Corvasal.RTM.) against 20 .mg of **PGE1** (Prostavasin.RTM.), both of them administered by intracavernous vias to 40 consecutive patient complaining of erectile failure. According to the latter author: ". . . SIN-1 is considerably less effective than **PGE1** and will therefore, not play a major role in the management of male impotence".

SUMM . . . pharmaceutical composition of an H.sub.2 receptor agonist and
a

pharmaceutically acceptable carrier or diluent in the treatment of male and **female sexual dysfunction** or impotence. A preferred pharmaceutical composition for use herein comprises the H.sub.2 agonist, N-[2-(5-Methyl-4-imidazolyl)methyl-thio)ethyl]-N'-[3-(4-imidazolyl)propyl]-guanidine) and pharmaceutically acceptable salts thereof (herein. . .

SUMM Another aspect of the present invention for treatment of male and **female sexual dysfunction** in a animal, including human beings is the use in such treatment of an H.sub.3 agonist, or a pharmaceutical composition. . . .

SUMM . . . are not limited to, paracrine mediators such as prostaglandins and analogs thereof having vasoactive functions, such as PGE.sub.1 and PGE.sub.2, **alprostadil** and **misoprostol**; histamine; peptides such as calcitonin gene related peptides (CGRP) or vasoactive intestinal peptide (VIP); calcium antagonists or blockers, such as. . .

SUMM As used herein "sexual dysfunction" refers to both male and **female sexual dysfunctions**, and includes for women organic dysfunctions related to clitoridal disturbances.

CLM What is claimed is:
27. A method of treating **female sexual dysfunction** in a human in need thereof which method comprises administering to said human an effective amount of an H.sub.2 agonist.

IT 50-60-2, Phentolamine 51-45-6, Histamine, biological studies 57-47-6,
Physostigmine 58-74-2, Papaverine 59-96-1, Phenoxybenzamine 59-99-4, Neostigmine 86-54-4, Hydralazine **745-65-3**, PGE1 14402-89-2, Sodium nitroprusside 15676-16-1, Sulpiride 37221-79-7, VIP 83652-28-2, CGRP
(erectogenic H2 histamine agonist in combination with, for treatment of sexual dysfunction)

L7 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER: 1999:63326 USPATFULL
TITLE: Compositions
INVENTOR(S): Nahoum, Cesar Roberto Dias, SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939

PATENT ASSIGNEE(S): Nahoum, Cesar Roberto Dias, Rio de Janeiro, Brazil (non-U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 5908853	19990601
	WO 9404120	19940303
APPLICATION INFO.:	US 1995-381945	19950215 (8)
	WO 1993-BR27	19930818
		19950215 PCT 371 date
		19950215 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	BR 1992-3277	19920821
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Harrison, Robert H.	
LEGAL REPRESENTATIVE:	Dinner, Dara L.; Venetianer, Stephen	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1523	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction** in an animal,

including humans. The H.sub.2 and H.sub.3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally. The method of use may also include a second therapeutic agent which either facilitates, potentiates or is erectogenic. The second agent may be administered sequentially or contemporaneously with either the H.sub.2 or H.sub.3 agonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . present invention involves the novel use of H.sub.2 and H.sub.3

agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction** in an animal, including humans. The H.sub.2 and H.sub.3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally.. . .

SUMM In 1986, Ishii et al injected for the first time **prostaglandin E.sub.1** into human corpora cavernosa for the treatment of organic impotence, Ishii, N. et al. "Therapeutic trial with **prostaglandin E.sub.1** for organic impotence". Jap. J. Imp., 1: 54-962 (1986). See also Ishii, N. et al "Intracavernous injection of **prostaglandin E.sub.1** for the treatment of erectile impotence". J. Urol., 141(2): 324-325 (1989). Since it is a drug of natural occurrence in. . .

SUMM . . . following the use of such a combination, von-Heyden et al. J. Urol., 149(5 Pt 2): 1288-1290 (1993). The use of **prostaglandin E.sub.1** is often rejected by patients because of the painfulness of its injection. Waldhauser, M. et al., J. Urol., 140(3): 525-527. .

SUMM . . . Impotence Res., 4(Suppl. 2): A91 (1992)) compared the erectogenic efficiency of 1 mg of SIN-1 (Linsindomin-Corvasal.RTM.) against 20 .mu.g of **PGE1** (Porstavasin.RTM.), both of them administered by intracavernous vias to 40 consecutive patient complaining of erectile failure. According to the latter author: " . .

SIN-1 is considerably bless effective than **PGE1** and will therefore, not play a major role in the management of male impotence".
DETD . . . pharmaceutical composition of an H.sub.2 receptor agonist and a

pharmaceutically acceptable carrier or diluent in the treatment of male and **female sexual dysfunction** or impotence. A preferred pharmaceutical composition for use herein comprises the H.sub.2 agonist, N-[2-(5-Methyl-4-imidazolyl)methyl-thio)ethyl]-N'-[3-(4-imidazolyl)propyl]-guanidine) and pharmaceutically acceptable salts thereof (herein. . .

DETD Another aspect of the present invention for treatment of male and **female sexual dysfunction** in a animal, including human beings is the use in such treatment of an H.sub.3 agonist, or a pharmaceutical composition. . .

DETD . . . are not limited to, paracrine mediates such as prostaglandins and analogs thereof having vasoactive functions, such as PGE.sub.1 and PGE.sub.2, **alprostadil** and **misoprostol**; histamine; peptides such as calcitonin gene related peptides (CGRP) or vasoactive intestinal peptide (VIP); calcium antagonists or blockers, such as. .

DETD As used herein "sexual dysfunction" refers to both male and **female sexual dysfunctions**, and includes for women orgasmic dysfunctions related to clitoridal disturbances.

DETD . . . the sequential administration of an H.sub.2 or H.sub.3 agonist and a second therapeutic agent for the treatment of male or **female sexual dysfunction**.

DETD . . . lower doses or multiple co-administered agents. As noted in WO 91/16021 where small intraurethral suppositories are utilized, individual titration of **PGE1** and prozasin were administered in multiple inserts. Similarly the H.sub.2 agonist alone or in combination with a second agent or. . .

DETD If a third agent, such as phentolamine, papaverine, **PGE1** or sulpiride is also administered the resulting dosage of histamine and Impromidine the reduction in doses of the H.sub.2 /H.sub.3. . .

IT 50-60-2, Phentolamine 51-45-6, Histamine, biological studies 57-47-6,
 Physostigmine 58-74-2, Papaverine 59-96-1, Phenoxybenzamine 59-99-4, Neostigmine 86-54-4, Hydralazine **745-65-3**, PGE1 14402-89-2, Sodium nitroprusside 15676-16-1, Sulpiride 37221-79-7, VIP 83652-28-2, CGRP
 (erectogenic H2 histamine agonist in combination with, for treatment of sexual dysfunction)

L7 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER: 1998:75603 USPATFULL
 TITLE: Compositions
 INVENTOR(S): Nahoum, Cesar Roberto Dias, SmithKline Beechman Corporation Corporate Intellectual Property, UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
 PATENT ASSIGNEE(S): Nahoum, Cesar Roberto Dias, Rio de Janeiro, Brazil (non-U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 5773457	19980630
APPLICATION INFO.:	US 1995-444130	19950518 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-381945, filed on 15 Feb 1995	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Reamer, James H.	
LEGAL REPRESENTATIVE:	Dinner, Dara L.; Venetianer, Stephen; Lentz, Edward T.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1454	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction**.

SUMM . . . time prustaglandin E.sub.1 into human corpora cavernosa for the treatment of organic impotence, Ishii, N. et al. "Therapeutic trial with **prostaglandin E.sub.1** for organic impotence". Jap. J. Imp., 1:54-962 (1986). See also Ishii, N. et al "Intracavernous injection of **prostaglandin E.sub.1** for the treatment of erectile impotence". J. Urol., 141(2):323-325 (1989). Since it is a drug of natural occurrence in the. . .

SUMM . . . reported following the use of such a combination, von-Heyden et

al. J. Urol., 149(5 Pt 2):1288-1290 (1993). The use of **prostaglandin E.sub.1** is often rejected by patients because of the painfulness of its injection. Waldhauser, M. et al., J. Urol., 140(3):525-527 (1988).

SUMM . . . Impotence Res., 4(Suppl. 2): A91 (1992)) compared the erectogenic efficiency of 1 mg of SIN-1 (Linsindomin-Corvasal.RTM.) against 20 .mu.g of **PGE1** (Prostavasin.RTM.), both of them administered by intracavernous vias to 40 consecutive patient complaining of erectile failure. According to the latter author: ". . . SIN-1 is considerably less effective than **PGE1** and will therefore, not play a major role in the management of male impotence".

DETD . . . pharmaceutical composition of an H.sub.2 receptor agonist and a

pharmaceutically acceptable carrier or diluent in the treatment of male and **female sexual dysfunction** or impotence. A preferred pharmaceutical composition for use herein comprises the H.sub.2 agonist, N-[2-(5-Methyl-4-imidazolyl)methyl-thio)ethyl]-N'-[3-(4-imidazolyl)propyl]-guanidine) and pharmaceutically acceptable salts thereof (herein. . .

DETD Another aspect of the present invention for treatment of male and **female sexual dysfunction** in a animal, including human beings is the use in such treatment of an H.sub.3 agonist, or a pharmaceutical composition. . .

DETD . . . are not limited to, paracrine mediators such as prostaglandins and analogs thereof having vasoactive functions, such as PGE.sub.1 and PGE.sub.2, **alprostadil** and **misoprostol**; histamine; peptides such as calcitonin gene related peptides (CGRP) or vasoactive intestinal peptide (VIP); calcium antagonists or blockers, such as. .

DETD As used herein "sexual dysfunction" refers to both male and **female sexual dysfunctions**, and includes for women orgasmic dysfunctions related to clitoridal disturbances.

DETD . . . the sequential administration of an H.sub.2 or H.sub.3 agonist and a second therapeutic agent for the treatment of male or **female sexual dysfunction**.

DETD . . . lower doses or multiple co-administered agents. As noted in WO 91/16021 where small intraurethral suppositories are utilized, individual titration of **PGE1** and prozasin were administered in multiple inserts. Similarly the H.sub.2 agonist alone or in combination with a second agent or. . .

DETD If a third agent, such as phentolamine, papaverine, **PGE1** or sulpiride is also administered the resulting dosage of histamine and Impromidine the reduction in doses of the H.sub.2 /H.sub.3. . .

IT 50-60-2, Phentolamine 51-45-6, Histamine, biological studies 51-45-6D, Histamine, analogs 57-47-6, Physostigmine 58-74-2, Papaverine 59-33-6 59-96-1, Phenoxybenzamine 59-99-4, Neostigmine 86-54-4, Hydralazine 113-92-8 **745-65-3**, **PGE1** 14402-89-2, Sodium nitroprusside 15676-16-1, Sulpiride 37221-79-7, Vasoactive intestinal peptide 55273-05-7, Impromidine 65119-89-3, Dimaprit 65573-02-6, Impromidine trihydrochloride 75614-87-8, (R)-.alpha.-Methylhistamine 83652-28-2, Calcitonin gene-related peptide 154962-59-1 (histamine receptor agonists for treatment of erectile dysfunction)

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.12

59.85

